The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1

Oncogene

Volumn 28, Issue 25, 2009, Pages 2406-2418

  Astanehe, A ^a   Finkbeiner, M R ^a   Hojabrpour, P ^b   To, K ^a   Fotovati, A ^a   Shadeo, A ^b   Stratford, A L ^a   Lam, W L ^b   Berquin, I M ^c   Duronio, V ^b   Dunn, S E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Invasion; PI3K; PIK3CA; UPA; YB 1

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN; PROTEIN P110; PROTEIN P110ALPHA; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UROKINASE; Y BOX BINDING PROTEIN 1;

ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL INVASION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DOWN REGULATION; ENZYME ACTIVITY; GEL MOBILITY SHIFT ASSAY; GENE AMPLIFICATION; GENE DISRUPTION; GENE INDUCTION; GENE MUTATION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; Y-BOX-BINDING PROTEIN 1;

EID: 67649986048     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.81     Document Type: Article

References (44)

1. Anjum R, Blenis J. (2008). The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 9: 747-758. Astanehe A, Arenillas D, Wasserman WW, Leung PC, Dunn SE,
2. Davies BR et al. (2008). Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. J Cell Sci 121: 664-674.
3. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S et al. (2004). The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3: 772-775.
4. Bader AG, Kang S, Vogt PK. (2006). Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 103: 1475-1479.
5. Carriere A, Ray H, Blenis J, Roux PP. (2008). The RSK factors of activating the Ras/MAPK signaling cascade. Front Biosci 13: 4258-4275.
6. Clark DE, Errington TM, Smith JA, Frierson HF, Weber MJ, Lannigan DA. (2005). The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Cancer Res 65: 3108-3116.
7. Deleeuw RJ, Zettl A, Klinker E, Haralambieva E, Trottier M, Chari R et al. (2007). Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology 132: 1902-1911.
8. Didier DK, Schiffenbauer J, Woulfe SL, Zacheis M, Schwartz BD. (1988). Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. Proc Natl Acad Sci USA 85: 7322-7326.
9. Dunn SE, Torres JV, Oh JS, Cykert DM, Barrett JC. (2001). Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. Cancer Res 61: 1367-1374.
10. Finkbeiner MR, Astanehe A, To K, Fotovati A, Davies AH, Zhao Y et al. (2009). Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene 28: 1421-1431.
11. Ghoda L, Lin X, Greene WC. (1997). The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IkappaBalpha and stimulates its degradation in vitro. J Biol Chem272: 21281-21288.
12. Gold MR, Duronio V, Saxena SP, Schrader JW, Aebersold R. (1994). Multiple cytokines activate phosphatidylinositol 3-kinase in hemopoietic cells: association of the enzyme with various tyrosinephosphorylated proteins. J Biol Chem 269: 5403-5412.
13. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B et al. (2007). Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129: 957-968.
14. Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D et al. (2008). Re-defining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res 10: R86.
15. Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M. (2007). Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res 5: 195-201.
16. Horn S, Bergholz U, Jucker M, McCubrey JA, Trumper L, Stocking C et al. (2008). Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells. Oncogene 27: 4096-4106.
17. Hui RC, Gomes AR, Constantinidou D, Costa JR, Karadedou CT, Fernandez de Mattos S et al. (2008). The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression. Mol Cell Biol 28: 5886-5898.
18. Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV et al. (2005). Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65: 10992-11000.
19. Manning BD, Cantley LC. (2007). AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
20. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T et al. (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527.
21. Rayet B, Gelinas C. (1999). Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18: 6938-6947.
22. Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton J et al. (2007). RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 282: 14056-14064.
23. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X et al. (2005). PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65: 2554-2559.
24. Samuels Y, Velculescu VE. (2004). Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3: 1221-1224.
25. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
26. Shadeo A, Lam WL. (2006). Comprehensive copy number profiles of breast cancer cell model genomes. Breast Cancer Res 8: R9.
27. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C et al. (1999). PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21: 99-102.
28. She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR et al. (2008). Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to akt signaling. PLoS ONE 3: e3065.
29. Sliva D, Rizzo MT, English D. (2002). Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J Biol Chem 277: 3150-3157.
30. Smith JA, Poteet-Smith CE, Xu Y, Errington TM, Hecht SM, Lannigan DA. (2005). Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res 65: 1027-1034.
31. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA98: 10869-10874.
32. Stratford AL, Fry CJ, Desilets C, Davies AH, Cho YY, Li Y et al. (2008). Y-box binding protein-1 (YB-1) serine 102 is a downstream target of p90 ribosomal S6 kinase (RSK) in basal-like breast cancer cells. Breast Cancer Res 10: R99.
33. Stratford AL, Habibi G, Astanehe A, Jiang H, Hu K, Park E et al. (2007). Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res 9: R61.
34. Sunters A, Fernandez de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA et al. (2003). FoxO3a transcriptional regulation of bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem 278: 49795-49805.
35. Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E et al. (2005). Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorageindependent growth of breast cancer cells. Oncogene 24: 4281-4292.
36. Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR. (2002). Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol 22: 965-977.
37. Vanhaesebroeck B, Alessi DR. (2000). The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 346(Part 3): 561-576.
38. Woo MM, Salamanca CM, Minor A, Auersperg N. (2007). An improved assay to quantitate the invasiveness of cells in modified Boyden chambers. in vitro Cell Dev Biol Anim 43: 7-9.
39. Wu G, Xing M, Mambo E, Huang X, Liu J, Guo Z et al. (2005). Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 7: R609-R616.
40. Wu J, Stratford AL, Astanehe A, Dunn SE. (2007). YB-1 is a transcription/translation factor that orchestrates the oncogenome by hardwiring signal transduction to gene expression. Trans Oncogen 2: 49-65.
41. Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E et al. (2006). Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res 66: 4872-4879.
42. Yehiely F, Moyano JV, Evans JR, Nielsen TO, Cryns VL. (2006). Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med 12: 537-544.
43. Zhang H, Liu G, Dziubinski M, Yang Z, Ethier SP, Wu G. (2008). Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells. Breast Cancer Res Treat 112: 217-227.
44. Zhao JJ, Cheng H, Jia S, Wang L, Gjoerup OV, Mikami A et al. (2006). The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci USA 103: 16296-16300.